CCEL · XBRL financial data

Cryo-Cell International financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CCEL's year ends in late November)

In thousands of dollars	FY 2020Nov 30, 2020	FY 2021Nov 30, 2021	FY 2022Nov 30, 2022	FY 2023Nov 30, 2023	FY 2024Nov 30, 2024	FY 2025Nov 30, 2025
Cost of goods and services sold	9,657	8,990	8,792	8,442	7,948	7,377
Research and development	24	50	385	1,171	1,243	376
Selling, general and administrative	14,294	14,625	15,580	17,116	18,521	18,221
Operating income (loss)	7,662	4,003	4,024	(12,304)	3,480	482
Interest expense	1,544	1,379	1,522	1,237	1,865	2,066
Other income (expense)	1	0	2	3	7	53
Income tax expense (benefit)	1,415	528	548	(3,843)	2,402	92
Net income (loss)	3,625	2,084	2,771	(9,522)	402	(2,429)
Earnings per share, basic USD per share	0.48	0.26	0.33	(1.14)	0.05	(0.30)
Earnings per share, diluted USD per share	0.45	0.25	0.33	(1.14)	0.05	(0.30)
Weighted average shares, basic thousands of shares	7,544	8,137	8,466	8,341	8,131	8,069
Weighted average shares, diluted thousands of shares	8,140	8,362	8,484	8,341	8,213	8,069

Fiscal years (CCEL's year ends in late November)

In thousands of dollars	FY 2020Nov 30, 2020	FY 2021Nov 30, 2021	FY 2022Nov 30, 2022	FY 2023Nov 30, 2023	FY 2024Nov 30, 2024	FY 2025Nov 30, 2025
Cash and cash equivalents	10,361	8,263	1,704	406	561	319
Marketable securities	88	75	18	574	2,935	2,977
Accounts receivable	6,323	5,253	6,044	6,576	7,309	6,846
Inventory	927	921	851	769	658	409
Total current assets	18,556	15,783	9,610	9,453	12,555	11,758
Property and equipment, net	1,641	3,230	13,603	20,997	21,894	21,034
Right-of-use asset	299	916	606	1,033	806	820
Goodwill	1,941	1,941	1,941	1,941	1,941	1,941
Total assets	46,200	60,662	64,888	61,221	64,678	61,729
Accounts payable	957	1,490	1,605	3,175	1,882	2,871
Accrued liabilities	2,898	3,057	3,586	5,171	5,810	4,278
Total current liabilities	16,415	21,074	19,481	20,864	21,600	19,793
Lease liability, non-current	24	611	313	852	505	475
Total liabilities	48,865	56,478	66,412	72,252	77,894	80,334
Accumulated deficit	(18,820)	(16,736)	(21,638)	(31,159)	(32,778)	(38,438)
Total stockholders' equity	(2,665)	4,184	(1,524)	(11,031)	(13,216)	(18,606)
Total liabilities and equity	46,200	60,662	64,888	61,221	64,678	61,729
Common shares outstanding (cover page) thousands of shares	7,571	8,503	8,443	8,287	8,082	8,055

Fiscal years (CCEL's year ends in late November)

In thousands of dollars	FY 2020Nov 30, 2020	FY 2021Nov 30, 2021	FY 2022Nov 30, 2022	FY 2023Nov 30, 2023	FY 2024Nov 30, 2024	FY 2025Nov 30, 2025
Net income (loss)	3,625	2,084	2,771	(9,522)	402	(2,429)
Stock-based compensation	622	302	461	817	781	417
Depreciation and amortization	372	1,039	1,499	1,400	694	985
Net cash from operating activities	8,467	7,926	8,573	8,920	6,011	5,479
Purchases of property and equipment	100	1,834	12,168	6,839	2,404	230
Net cash from investing activities	357	(6,951)	(15,280)	(8,145)	(4,877)	(975)
Share repurchases	—	249	1,820	799	1,424	170
Dividends paid	—	0	7,673	0	2,021	3,231
Net cash from financing activities	(5,004)	(3,073)	148	(2,073)	(979)	(4,745)

SIC 8090 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8090 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cryo Cell International	1,426	7,824	1,142*	8.1M	—	Q3 FY26 10-QAug 31, 2026
Elite Health Systems	1,302	1,310	(1,353)*	28.5M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Mangoceuticals	229	69	(261)*	21.6M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
BioRestorative Therapies	3,113	23	(3,808)	25.5M	0.9 quarters	Q1 FY26 10-QMar 31, 2026
Marpai	138	4,166	(4,099)*	26.8M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Quipt Home Medical	10,543	80,996	8,941	44.5M	—	Q1 FY26 10-QDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.